文献速递肝病

经验证的早期检测指标可减少需肝纤维化筛查的人群

Validated Early Detection Metrics Reduce the Population Requiring Liver Fibrosis Screening.
PubMed 文献 · Gastroenterology · 2026-06-15

研究基于NHANES 2017–2020数据,在5904名无过量饮酒成人中评估肝纤维化筛查指标,提出仅针对LSM≥8 kPa风险≥10%的亚组进行筛查的优化策略。该策略将筛查目标人群从指南的60%–76%降至22%,使筛查合格者LSM≥8 kPa患病率从11%–14%升至28%,并在4个队列(n=13,295)及UK Biobank(n=282,852)中验证,合格者10年肝硬化及肝相关死亡风险约高6倍。

要点

  • 现行指南使60%–76%成人符合筛查条件,优化策略仅针对22%。
  • 优化策略下筛查合格者LSM≥8 kPa患病率升至28%,不合格者仅4%。
  • UK Biobank中合格者10年肝硬化风险0.99% vs 0.18%。

核心结论

  • 现行指南推荐筛查60%–76%成人,优化策略将目标人群降至10%–22%,并提高筛查合格者的疾病患病率。

研究设计与样本

  • 推导队列为NHANES 2017–2020 pre-pandemic数据中18–80岁、BMI≥18.5 kg/m2且无过量饮酒的成人5904名。
  • 优化标准在4个一般人群队列(汇总n=13,295)中验证,并与肝脏相关事件关联。
  • 另在英国生物银行(UK Biobank,n=282,852)中评估10年肝硬化及肝相关死亡风险。

主要发现

  • 推导队列中8.9%的成人LSM≥8 kPa;现行指南识别60%–76%为筛查合格,合格者LSM≥8 kPa患病率11%–14%,不合格者2%。
  • 优化策略针对22%人群筛查,合格者LSM≥8 kPa患病率28%,不合格者4%。
  • 汇总验证队列中7.0% LSM≥8 kPa,14%符合优化标准;合格者LSM≥8、≥10、≥12 kPa患病率分别为22%、13%、8%,不合格者分别为4%、2%、1%。
  • UK Biobank中符合优化标准者10年新发肝硬化风险0.99% vs 0.18%,肝相关死亡风险0.40% vs 0.07%,约高6倍。

关键数值与推荐

  • 优化策略仅针对LSM≥8 kPa风险≥10%的亚组进行筛查。
  • 优化策略将筛查目标人群从指南的60%–76%降至10%–22%。
  • 筛查合格者LSM≥8 kPa患病率28%,不合格者4%;阈值≥10、≥12 kPa时合格者分别为13%、8%,不合格者2%、1%。

临床怎么用

  • 可采用优化标准先识别LSM≥8 kPa风险≥10%的亚组,再行肝纤维化筛查,以减少需筛查人群。
  • 优化标准不合格者LSM升高及肝相关事件风险很低,可避免不必要的筛查。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Current guideline-defined indicators for fibrosis screening identify a large proportion of the general population, burdening health care resources. We aimed to evaluate and refine indicators for fibrosis screening. METHODS: We included adults aged 18-80 years from the National Health and Nutrition Examination Survey 2017-March 2020 pre-pandemic data with a body mass index ≥18.5 kg/m2 without excessive alcohol use. We obtained the weighted proportions of individuals across stratified screening indicators and targeted only subgroups with ≥10% liver stiffness measurement (LSM ≥8 kPa) risk for screening. These refined criteria were validated and linked with liver-related events in 4 general-population cohorts. RESULTS: The derivation cohort included 5904 adults (8.9% LSM ≥8 kPa). Current guidelines identified 60%-76% as screening-eligible, yielding an LSM ≥8 kPa prevalence of 11%-14% among those screening eligible and 2% among those not eligible. Our refined strategy targeted 22% for screening, increasing prevalence to 28% among those screening-eligible, while maintaining low prevalence (4%) in those not eligible. In the pooled validation cohort (n = 13,295; 7.0% LSM ≥8 kPa), 14% met the refined criteria. Results remained consistent across thresholds: LSM ≥8, ≥10, and ≥12 kPa prevalence among screening-eligible individuals was 22%, 13%, and 8%, respectively, and 4%, 2%, and 1% among those not eligible. In the UK Biobank (n = 282,852), individuals meeting the refined criteria had an approximately 6-fold higher 10-year risk of incident cirrhosis (0.99% vs 0.18%) and liver-related death (0.40% vs 0.07%). CONCLUSIONS: Current recommendations target 60%-76% of adults for fibrosis screening. Our refined strategy reduced this to 10%-22%, achieving significantly higher disease prevalence among those eligible for screening, while maintaining a very low risk of increased LSM or liver-related events in those not eligible for screening.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. van Kleef LA, Pustjens J, Schneider CV, et al. Validated Early Detection Metrics Reduce the Population Requiring Liver Fibrosis Screening. Gastroenterology. 2026. PMID: 42297049. doi:10.1053/j.gastro.2026.06.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。